John Sweetenham, MD, PhD

Editorials by John Sweetenham, MD

Editorial

Reflections on the value of new cancer drugs: The role of the man in the mirror

HemOnc Today, March 10, 2017
John Sweetenham, MD
The cost of cancer drugs has been the subject of intense interest and scrutiny. This is no surprise as the focus on value in cancer care increases…
Editorial

Despite challenges in US cancer care, things could be a lot worse

HemOnc Today, February 10, 2017
John Sweetenham, MD
“When my bankroll is getting small I think of when I had none at all
Editorial

Valuing communication and communicating value: Staying in touch with our patients’ priorities

HemOnc Today, January 10, 2017
John Sweetenham, MD
Although the presidential election result has raised questions about the direction of health care reform, most experts believe that value will remain…
Editorial

Doing the same thing over and over again but expecting different results: It’s time to move on

HemOnc Today, November 25, 2016
John Sweetenham, MD
A publication in Journal of Clinical Oncology reports the results of a randomized trial that compared rituximab, cyclophosphamide, doxorubicin…
Editorial

Cancer screening: The stars are aligned

HemOnc Today, November 10, 2016
John Sweetenham, MD
In recent weeks, important new studies have added more data to the ongoing debate about the effectiveness of screening programs for breast cancer and…
Editorial

Missing emails: How we set the record straight

HemOnc Today, October 10, 2016
John Sweetenham, MD
In an election year in which missing emails and cybersecurity have attracted a frenzy of media attention, I was recently thinking about my own email…
Editorial

End games, Charles Nesbitt Wilson and cancer survivorship

HemOnc Today, September 10, 2016
John Sweetenham, MD
The movie Charlie Wilson’s War, based on the book of the same name by George Crile III, depicts the story of Charles Nesbitt Wilson. Wilson…
Editorial

Balancing hope and realism: It may be time to adjust the sails

HemOnc Today, August 10, 2016
John Sweetenham, MD
Events of recent weeks have kept the focus of the oncology community in the United States on President Barack Obama’s national cancer moonshot…
Editorial

ASCO: A mixed bag of positives, negatives, promises for the future

HemOnc Today, July 10, 2016
John Sweetenham, MD
In years past, I have avoided using my monthly editorial to provide a report from the ASCO Annual Meeting, partly because the content from the…
Editorial

It’s good to share, both in research and in life

HemOnc Today, June 10, 2016
John Sweetenham, MD
As I reflect on the ASCO Annual Meeting — specifically the new data presented and what I learned this year — I think of it as the…